Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6OP5

Crystal Structure of Piper methysticum Styrylpyrone Synthase 1 in complex with p-coumaroyl-CoA

Replaces:  6CO0
Summary for 6OP5
Entry DOI10.2210/pdb6op5/pdb
Related6CQB 6NBR
DescriptorStyrylpyrone synthase 1, p-coumaroyl-CoA, ... (4 entities in total)
Functional Keywordskavalactone biosynthesis, phenylpropanoid pathway, transferase
Biological sourcePiper methysticum
More
Total number of polymer chains6
Total formula weight263442.46
Authors
Pluskal, T.,Weng, J.K. (deposition date: 2019-04-24, release date: 2019-06-12, Last modification date: 2025-04-02)
Primary citationPluskal, T.,Torrens-Spence, M.P.,Fallon, T.R.,De Abreu, A.,Shi, C.H.,Weng, J.K.
The biosynthetic origin of psychoactive kavalactones in kava.
Nat.Plants, 5:867-878, 2019
Cited by
PubMed Abstract: Kava (Piper methysticum) is an ethnomedicinal shrub native to the Polynesian islands with well-established anxiolytic and analgesic properties. Its main psychoactive principles, kavalactones, form a unique class of polyketides that interact with the human central nervous system through mechanisms distinct from those of conventional psychiatric drugs. However, an unknown biosynthetic machinery and difficulty in chemical synthesis hinder the therapeutic use of kavalactones. In addition, kava also produces flavokavains, which are chalconoids with anticancer properties structurally related to kavalactones. Here, we report de novo elucidation of the key enzymes of the kavalactone and flavokavain biosynthetic network. We present the structural basis for the evolutionary development of a pair of paralogous styrylpyrone synthases that establish the kavalactone scaffold and the catalytic mechanism of a regio- and stereo-specific kavalactone reductase that produces a subset of chiral kavalactones. We further demonstrate the feasibility of engineering styrylpyrone production in heterologous hosts, thus opening a way to develop kavalactone-based non-addictive psychiatric therapeutics through synthetic biology.
PubMed: 31332312
DOI: 10.1038/s41477-019-0474-0
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.7 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon